IP Library Granted Patent US 9,415,113
Granted Patent B2
US 9,415,113 · App. 13/510,279 · Granted Aug 16, 2016

Targeting monomers and polymers having targeting blocks

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,415,113
App. No.
13/510,279
Granted
Aug 16, 2016
Kind
B2
Abstract

Provided herein are monomers incorporating folate or other targeting agent, polymers prepared therefrom, polymers prepared therefrom having a therapeutic agent covalently coupled thereto, as well as micelles and therapeutic compositions thereof.

Claims (20)

1. A monomer of Formula M1

wherein

M 1 and M 2 are independently selected from the group consisting of hydrogen, hydrocarbyl, substituted hydrocarbyl, heterocyclo, and substituted carbonyl, provided, however, M 1 and M 2 are not each selected from the group consisting of aryl, heteroaryl, and heterosubstituted carbonyl;

M 3 is hydrogen, hydrocarbyl, substituted hydrocarbyl, heterocyclo, or substituted carbonyl, and

M 4 is —C(O)OM 40 , —C(O)SM 40 , —C(O)NM 40 M 41 , —Ar-M 40 or -Het-M 40 , Ar is arylene, Het is heteroarylene, M 41 is hydrogen, hydrocarbyl, substituted hydrocarbyl, heterohydrocarbyl, substituted heterohydrocarbyl, or heterocyclo, and M 40 contains, as a terminal moiety, a targeting moiety selected from the group consisting of folate and folate analogs, provided M 3 and M 4 are not each selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, and heterosubstituted carbonyl.

2. The monomer of claim 1 wherein M 3 is hydrogen, methyl, ethyl, or propyl.

3. The monomer of claim 1 wherein M 40 is a substituted hydrocarbyl or a substituted heterohydrocarbyl containing the terminal targeting moiety.

4. The monomer of claim 1 wherein M 3 is hydrogen, methyl, ethyl, or propyl; and M 40 is a substituted hydrocarbyl or a substituted heterohydrocarbyl containing the terminal targeting moiety.

5. The monomer of claim 1 wherein M 3 is hydrogen, methyl, ethyl, or propyl; and M 4 is —C(O)OM 40 , —C(O)SM 40 , or —C(O)NM 40 M 41 .

6. The monomer of claim 1 wherein M 40 contains, as the terminal targeting moiety, a moiety having the formula

wherein the symbol, , designates the point of attachment of the targeting moiety to the remainder of M 40 , T 4 is hydroxy, optionally substituted alkoxy, or amino, T 5 is hydrogen or alkyl, and T 6 is hydrogen or optionally substituted alkyl.

7. A monomer of Formula M10

wherein M 3 is hydrogen, hydrocarbyl, substituted hydrocarbyl, heterocyclo, or substituted carbonyl; Y is a bond or a linking group selected from the group consisting of hydrocarbylene, substituted hydrocarbylene, heterohydrocarbyl, and substituted heterohydrocarbyl; T 4 is hydroxy, optionally substituted alkoxy, or amino; T 5 is hydrogen or alkyl, T 6 is hydrogen, alkyl, substituted alkyl, heterohydrocarbyl, or substituted heterohydrocarbyl; Z is —C(O)O—, —C(O)S—, —C(O)N(M 41 )-, —Ar-M 49 - or Het-M 49 -; Ar is arylene; Het is heteroarylene; M 41 is hydrogen, hydrocarbyl, substituted hydrocarbyl, heterohydrocarbyl, substituted heterohydrocarbyl, or heterocyclo; M 49 is oxygen, sulfur, or —N(M 50 )-; and M 50 is hydrogen, hydrocarbyl or substituted hydrocarbyl.

8. The monomer of claim 7 wherein M 3 is hydrogen, methyl, ethyl, or propyl, T 4 is hydroxy, and T 5 and T 6 are hydrogen.

9. The monomer of claim 7 wherein M 3 and T 6 are independently hydrogen, methyl, ethyl, or propyl; Z is —C(O)O—, —C(O)S—, or —C(O)N(M 41 )-; and M 41 is hydrogen, hydrocarbyl, substituted hydrocarbyl, heterohydrocarbyl, substituted heterohydrocarbyl, or heterocyclo.

10. The monomer of claim 7 wherein Y is alkylene or (poly)alkylene oxide.

11. The monomer of claim 7 wherein M 3 and T 6 are independently hydrogen, methyl, ethyl, or propyl, Z is —C(O)O—, —C(O)S—, or —C(O)N(M 41 )-; Y is alkylene or (poly)alkylene oxide; and M 41 is hydrogen, hydrocarbyl, substituted hydrocarbyl, heterohydrocarbyl, substituted heterohydrocarbyl, or heterocyclo.

12. The monomer of claim 7 wherein Z is —C(O)O— or —C(O)S— and the is of Formula M11 or M12

wherein M 3 is hydrogen, methyl, ethyl, or propyl, Y is a linking group selected from the group consisting of hydrocarbylene, substituted hydrocarbylene, heterohydrocarbyl, and substituted heterohydrocarbyl; T 4 is hydroxy, optionally substituted alkoxy, or amino; T 5 is hydrogen or alkyl, and T 6 is hydrogen, alkyl or substituted alkyl.

13. The monomer of claim 5 , wherein M 40 is a substituted hydrocarbyl or a substituted heterohydrocarbyl containing the terminal targeting moiety.

Assignments (6)
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Apr 3, 2020
From: GENEVANT SCIENCES LTD.
To: ROIVANT SCIENCES LTD.
Reel/Frame 052312/0930 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 12, 2018
From: PHASERX, INC.
To: ROIVANT HEPATOLOGY GMBH
Reel/Frame 047649/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 12, 2018
From: ROIVANT HEPATOLOGY GMBH
To: GENEVANT SCIENCES GMBH
Reel/Frame 047689/0406 →
CONFIRMATORY LICENSE Recorded Aug 16, 2012
From: UNIVERSITY OF WASHINGTON / CENTER FOR COMMERICALIZATION
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 028801/0337 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 10, 2012
From: STAYTON, PATRICK S.; HOFFMAN, ALLAN S.
To: WASHINGTON, UNIVERSITY OF
Reel/Frame 028762/0320 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 10, 2012
From: MONAHAN, SEAN D.; JOHNSON, PAUL H.; DECLUE, MICHAEL S.; DE, PRIYADARSI; GALL, ANNA S.; DIAB, CHARBEL
To: PHASERX, INC.
Reel/Frame 028762/0468 →